Background: Epidemiological studies of neuropsychiatric events (NPEs) associated with leukotriene receptor antagonists (LTRAs) have yielded inconsistent results. Recent studies have demonstrated strong temporal relationships between LTRA prescription and NPE occurrence, indicating a need for further investigation.
Objective: To investigate potential LTRA-related NPEs and associated risk factors.
Methods: Adults with asthma or rhinitis were enrolled from the Korean claims database. The temporal relationship between the first NPE diagnosis and the last LTRA prescription before NPE was evaluated. Nested case-control studies for NPEs and suicide were conducted. Cases (those with NPEs) were matched to controls for age and sex to compare the frequency of LTRA prescription in the lag time before NPE diagnosis. The risk factors for LTRA-related NPEs (developed within 6 months of LTRA prescription) were assessed in people on LTRAs by comparing those with LTRA-related NPEs to those on LTRAs who did not have NPEs.
Results: Montelukast and pranlukast were more frequently prescribed within 6 months before NPEs (odds ratio, 1.31, 95% CI, 1.21-1.41, and odds ratio, 1.25, 95% CI, 1.15-1.35). Older adults, low income, high comorbidity burden, and asthma exhibited stronger associations with LTRA-related NPEs than with general NPEs. Sleep disturbances appeared more prevalent in LTRA-related NPEs than in other NPEs. An LTRA prescription within 6 months was associated with suicide in univariate but not in multivariate analysis.
Conclusions: Increased neuropsychiatric risk was observed within 6 months after LTRA prescription. LTRA may lower the threshold for NPEs in those at risk for NPEs, irrespective of sex.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2024.09.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Appropriate Allergic Rhinitis Medications Can Reduce Systemic Steroid Requirement and Prevent Rhinosinusitis.
J Clin Med
November 2024
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea.
: Allergic rhinitis (AR) is quite common and sometimes it requires systemic steroids and can be accompanied by coronavirus disease-2019 (COVID-19), rhinosinusitis, or asthma. We aimed to determine the comparative effect of different types of AR medications on clinical prognosis in real-world settings. : We used national claims data provided by the National Health Insurance Service in the Republic of Korea.
View Article and Find Full Text PDFNeuropsychiatric Events Related to Montelukast and Pranlukast in Adults With Asthma and Rhinitis: A 10-Year Nationwide Population-Based Study.
J Allergy Clin Immunol Pract
September 2024
Division of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, Korea. Electronic address:
Background: Epidemiological studies of neuropsychiatric events (NPEs) associated with leukotriene receptor antagonists (LTRAs) have yielded inconsistent results. Recent studies have demonstrated strong temporal relationships between LTRA prescription and NPE occurrence, indicating a need for further investigation.
Objective: To investigate potential LTRA-related NPEs and associated risk factors.
The impact of adenotonsillectomy on healthcare utilization in children with obstructive sleep apnea: Experience of an integrated medical model.
Int J Pediatr Otorhinolaryngol
June 2024
Kaiser Permanente, Pediatric Pulmonology and Sleep Medicine, Santa Clara, CA, USA.
Article Synopsis
- A study investigates how adenotonsillectomy (AT) affects healthcare utilization in children aged 3-12 diagnosed with obstructive sleep apnea (OSA), revealing a gap in previous research regarding OSA severity groups.
- The research used retrospective data from 577 children, analyzing their medical visits and prescription patterns before and after undergoing surgery, utilizing methods like difference-in-difference models to assess impact.
- Results indicate that the healthcare utilization patterns of children with OSA are poorly understood post-surgery, emphasizing the need for more in-depth analysis on the implications of surgical treatments.
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data.
Mult Scler
May 2024
Center for Precision Health, McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA/Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Background: Effective and safe treatment options for multiple sclerosis (MS) are still needed. Montelukast, a leukotriene receptor antagonist (LTRA) currently indicated for asthma or allergic rhinitis, may provide an additional therapeutic approach.
Objective: The study aimed to evaluate the effects of montelukast on the relapses of people with MS (pwMS).
Increased Risk of Tourette Syndrome with Leukotriene Modifier Use in Children with Allergic Diseases and Asthma: A Nationwide Population-Based Study.
Children (Basel)
October 2022
Department of Pediatrics, Taipei Medical University Hospital, Taipei 110, Taiwan.
Article Synopsis
- Cysteinyl leukotriene receptor antagonists (LTRAs) like montelukast and zafirlukast are FDA-approved to treat children's asthma and allergic conditions, but their link to Tourette syndrome (TS) in kids is explored in this study.
- The research analyzed medical records of nearly 27,000 children under 18 who were treated for allergic diseases and asthma between 2005 and 2018, comparing those on LTRAs with those not on the medication.
- Findings revealed that children using LTRAs had a significantly higher risk of developing TS compared to non-users, highlighting the need for further study on the neuropsychiatric impacts of these drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!